Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125393 | 0.78 | KMT2A (0.39) | ITGAVCCR4KMT2AMCOLN3PGR | |
| SCHEMBL5111771 | 0.76 | MCOLN3 (0.49) | ITGAVCCR4KMT2AMCOLN3HSD11B1 | |
| SCHEMBL5125440 | 0.73 | BDKRB1 (0.47) | — | |
| SCHEMBL4035633 | 0.73 | BDKRB1 (0.68) | — | |
| SCHEMBL5377341 | 0.70 | CDC25A (0.43) | ITGAVMCOLN3PGR | |
| SCHEMBL28530573 | 0.70 | CA12 (0.45) | ITGAVKMT2AMCOLN3PGR | |
| SCHEMBL5111162 | 0.69 | CDC25A (0.45) | ITGAV | |
| SCHEMBL5125397 | 0.68 | BDKRB1 (0.55) | KMT2AMCOLN3HSD11B1NR1H4 | |
| SCHEMBL5114277 | 0.68 | ALDH1A1 (0.40) | ITGAVKMT2APGR | |
| SCHEMBL5115200 | 0.68 | FABP4 (0.46) | ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NR3C1 779/4885ITGAV 2712/4885CCR4 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.